From HealthNewsDigest.com

Cancer Issues
How Cancer Cells Thrive in Oxygen-Starved Tumors
By
Feb 6, 2014 - 10:39:27 AM

(HealthNewsDigest.com) - COLUMBUS, Ohio - A new study identifies the molecular pathway that enables cancer cells to grow in areas of a tumor where oxygen levels are low, a condition called hypoxia.

The findings by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), might offer a new strategy for inhibiting tumor growth by developing agents that reverse this hypoxia-related pathway.

The study focuses on how cancer cells use the amino acid glutamine, the most common amino acid found free in the bloodstream. Under normal oxygen levels, healthy cells use glutamine largely to produce energy, with a small amount diverted to make fatty acids and lipids.

But when oxygen levels drop in areas of a growing tumor, the hypoxic conditions activate a gene called HIF1, initiating a pathway that shifts the use of glutamine away from energy production and to the synthesis of lipids needed for cell proliferation.

The findings were published in the journal Cell Metabolism.

"These results are particularly exciting because glutamine metabolism is a potential target for anticancer therapy," says principal investigator Nicholas Denko, PhD, MD, associate professor of radiation oncology at the OSUCCC - James.

"Tumor cells require glutamine to grow, so groups have been trying to identify drugs that block glutamine metabolism and inhibit tumor growth. However, drugs that completely block glutamine metabolism will have unwanted side effects because glutamine is also an important neurotransmitter," he says.

"We show that we can block the growth of model tumors by redirecting hypoxic glutamine metabolism to make it follow the normal-oxygen pathway. Such a therapeutic strategy should have few-if-any unwanted side effects, because normal tissue is oxygenated and already using glutamine in the normal manner," says Denko, who is a member of the OSUCCC - JamesMolecular Biology and Cancer Genetics Program.

Denko and first author Ramon C. Sun, a postdoctoral researcher in radiation oncology, used several tumor-cell lines and an animal model for this study. Their key findings include:

Funding from the NIH/National Cancer Institute (grant P01 CA67166) supported this research.

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State's cancer program as "exceptional," the highest rating given by NCI survey teams. As the cancer program's 228-bed adult patient-care component, The James is a "Top Hospital" as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.

###


For advertising and promotion on HealthNewsDigest.com, call Mike McCurdy: 877-634-9180 or [email protected] We have over 7,000 journalists as subscribers.

 



© Copyright by HealthNewsDigest.com